MIDTERM OUTCOMES OF STENT RECOIL WITH STENT FRACTURE AFTER VARIOUS DRUG-ELUTING STENT IMPLANTATIONS

MIDTERM OUTCOMES OF STENT RECOIL WITH STENT FRACTURE AFTER VARIOUS DRUG-ELUTING STENT IMPLANTATIONS

A1514 JACC April 1, 2014 Volume 63, Issue 12 Stable Ischemic Heart Disease Midterm Outcomes of Stent Recoil with Stent Fracture after Various Drug-El...

849KB Sizes 0 Downloads 43 Views

A1514 JACC April 1, 2014 Volume 63, Issue 12

Stable Ischemic Heart Disease Midterm Outcomes of Stent Recoil with Stent Fracture after Various Drug-Eluting Stent Implantations Moderated Poster Contributions Hall C Sunday, March 30, 2014, 10:00 a.m.-10:15 a.m.

Session Title: Stable Ischemic Heart Disease: Percutaneous Revascularization Abstract Category: 25. Stable Ischemic Heart Disease: Clinical Presentation Number: 1204M-365B Authors: Masanobu Ohya, Kazushige Kadota, Takeshi Tada, Seiji Habara, Hiroyuki Tanaka, Yasushi Fuku, Tsuyoshi Goto, Kazuaki Mitsudo, Kurashiki Central Hospital, Kurashiki, Okayama, Japan Background: Stent fracture (SF) after drug-eluting stent (DES) implantation has been reported to be associated with target lesion revascularization. We have proposed stent axial recoil at lesions of DES implantation, especially at SF lesions and named it stent recoil (SR). We evaluated the midterm outcomes of SR with SF after various DES implantations. Methods and Results: The study population consisted of 11617 lesions (5068 patients) that were treated exclusively with DES from 2003 to 2012. Midterm follow-up angiography was scheduled at 8 months after procedure. SF was defined as the separation of stent segments or stent struts. SR was defined as axial recoil less than 80% in stent diameter. SF was observed in 494 lesions (446 patients) and SR with SF in 138 lesions (129 patients). As the figure shows, the incidence of SR with SF after biolimus-eluting stent implantation was significantly lower than those after sirolimus-eluting, paclitaxel-eluting, and Pt-Cr everolimus-eluting stent implantations (13.4%, 29.0%, 39.1%, and 54.5%, respectively). On the other hand, regardless of DES type, the rate of restenosis and target lesion revascularization (TLR) at SR with SF lesions were higher than those at non-SR with SF lesions. Conclusion: The incidence of SR in SF lesions could be related to DES type. SR appears to affect the midterm outcomes of SF lesions regardless of DES type.